You are here

Novartis

11 promising drugs poised to be the next billion-dollar blockbusters

Yahoo/Business Insider

Sat, 03/28/15 - 10:26 am

Psoriasis data wars heat up at AAD with Novartis, Boehringer studies

Fierce Pharma Marketing

Thu, 03/26/15 - 07:38 am

Boehringer Ingelheim

Amgen to appeal rejection of bid to block Novartis biosimilar drug

Yahoo/Reuters

Wed, 03/25/15 - 03:18 pm

Opdivo, Praluent and LCZ-696 top a launch crop poised for $27B in sales

Fierce Pharma Marketing

Wed, 03/25/15 - 03:13 pm

Bristol-Myers Squibb

Novartis chief: Sometimes you have to kill your R&D darlings

Fierce Biotech

Wed, 03/25/15 - 09:02 am

Why 2015 is the year of the biopharma blockbuster—with charts

BioPharma Dive

Tue, 03/24/15 - 10:29 am

Bristol-Myers Squibb

Vertex Pharmaceuticals

Novartis, Lilly lead a $44M round for rare disease biotech Aeglea

Fierce Biotech

Tue, 03/24/15 - 10:22 am

Here comes the blockbuster: Novartis' Cosentyx bests Stelara in psoriasis trials

BioPharma Dive

Mon, 03/23/15 - 10:36 am

Bristol, Sanofi and Novartis drugs to shine among 2015 launches

Yahoo/Reuters

Mon, 03/23/15 - 09:21 am

Bristol-Myers Squibb. LCZ-696

U.S. judge rejects Amgen injunction bid against Novartis Sandoz unit

Yahoo/Reuters

Fri, 03/20/15 - 11:00 am

Top 15 pharma companies by 2014 revenue

Fierce Pharma

Wed, 03/18/15 - 11:04 am

Japanese doctor testifies on inflating placebo counts in Diovan trials

Fierce Pharma Asia

Tue, 03/17/15 - 07:13 pm

Novartis Pays $12.6M Fine for Giving Inaccurate Pricing Data to Medicare

WSJ Pharmalot

Mon, 03/16/15 - 03:00 pm

Novartis AG (ADR) Cosentyx More Effective Than Johnson & Johnson Stelara

Bidness Etc.

Sat, 03/14/15 - 03:04 pm

Cost watchdogs back Novartis' Xolair for big new market in chronic hives

Fierce Pharma

Thu, 03/12/15 - 09:36 pm

Novartis CEO eyes more cost cuts to satisfy margin demands

Fierce Pharma

Mon, 03/9/15 - 11:46 am

First-ever bio-generic drug doesn’t help Novartis shares

Marketwatch

Sun, 03/8/15 - 10:20 am

First Copycat Biotech Drug Spurs $250B Obamacare Savings

Forbes

Sat, 03/7/15 - 11:16 am

Is AbbVie (ABBV) Giving Up On Hepatitis C Market Due To Tough Competition From Gilead (GILD)?

Bidness Etc.

Sat, 03/7/15 - 11:07 am

Gilead Sciences

Novartis gets bragging rights on first U.S. biosim. But will its Neupogen copy sell?

Fierce Pharma

Fri, 03/6/15 - 11:27 am

biosimilars sector

Pages